SNG-12

SNG-12, also known as Synapsinae, is a glycine transporter 1 (GlyT1) inhibitor, or a glycine reuptake inhibitor, which is under development for the treatment of psychotic disorders, dementia, depressive disorders, and suicidal ideation.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

SNG-12, also known as Synapsinae, is a glycine transporter 1 (GlyT1) inhibitor, or a glycine reuptake inhibitor, which is under development for the treatment of psychotic disorders, dementia, depressive disorders, and suicidal ideation. As of September 2022, it is in phase 3 clinical trials for depressive disorders and suicidal ideation and is in phase 2 clinical rials for psychotic disorders and dementia.

The drug is under development by SyneuRx. It is described as a small molecule, but its chemical structure does not appear to have been disclosed.

See also

Bitopertin Iclepertin Tilapertin

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372046786 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.